Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy

被引：0

作者：

Christoph, Daniel ^{[1
]}

Girard, N. ^{[2
]}

Smit, H. J. M. ^{[3
]}

Sibille, A. ^{[4
]}

Mcdonald, F. ^{[5
]}

Mornex, F. ^{[6
]}

Garassino, M. C. ^{[7
]}

Filippi, A. R. ^{[8
,9
]}

Peters, S. ^{[10
]}

Field, J. K. ^{[11
]}

Haakensen, V. Drageset ^{[12
]}

Bar, J. ^{[13
]}

Chouaid, C. ^{[14
]}

Bray, V. ^{[15
]}

Kao, S. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[18
]}

Garrido, P. ^{[19
]}

Fietkau, R. ^{[20
]}

机构：

[1] Evang Huyssens Stiftung Essen Huttrop, Evang Kliniken Essen Mitte, Dept Med Oncol Hematol, Essen, Germany

[2] Inst Curie & Montsouris, Inst Thorax, Paris, France

[3] Rijnstate Hosp, Dept Pulm Dis, Arnhem, Netherlands

[4] Ctr Hosp Univ Liege, Dept Pneumol & Allergol, Liege, Belgium

[5] Royal Marsden NHS Fdn Trust, Lung Unit, London, England

[6] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[7] Univ Chicago, Dept Hematol Oncol, Chicago, IL USA

[8] Fdn IRCCS Policlin San Matteo, Radiat Oncol Dept, Pavia, Italy

[9] Univ Pavia, Pavia, Italy

[10] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

[11] Univ Liverpool, Roy Castle Lung Canc Res Programme, Dept Mol & Clin Canc Med, Liverpool, England

[12] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[13] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[14] CHI Creteil, Serv Pneumol, Creteil, France

[15] Liverpool Hosp, Dept Med Oncol, Liverpool, NSW, Australia

[16] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[17] AstraZeneca, Oncol, Med Affairs, Gaithersburg, MD USA

[18] AstraZeneca, Oncol, Med Affairs, Paris, France

[19] Univ Alcala, Hosp Ramon y Cajal, Madrid, Spain

[20] Univ Klinikums Erlangen, Dept Radiat Oncol, Erlangen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

256

引用

页码：151 / 151

页数：1

共 50 条

[1] PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Girard, N.
Smit, H. J. M.
Sibille, A.
McDonald, F.
Mornex, F.
Garassino, M. C. C.
Filippi, A. R.
Peters, S.
Field, J. K.
Christoph, D. C.
Fietkau, R.
Haakensen, V. D.
Bar, J.
Chouaid, C.
Bray, V.
Kao, S.
Sawyer, W.
Allen, A.
Licour, M.
Garrido, P.
ANNALS OF ONCOLOGY, 2021, 32 : S939 - S940
[2] Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy
Christoph, D. C.
Girard, N.
Smit, H. J. M.
Sibille, A.
McDonald, F.
Mornex, F.
Garassino, M. C.
Filippi, A. R.
Peters, S.
Field, J. K.
Haakensen, Drageset, V
Bar, J.
Chouaid, C.
Bray, V
Kao, S.
Sawyer, W.
Allen, A.
Licour, M.
Garrido, P.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 53
[3] PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
McDonald, F.
Mornex, F.
Garassino, M. C.
Filippi, A. R.
Christoph, D.
Haakensen, V. D.
Agbarya, A.
Van den Heuvel, M.
Vercauter, P.
Chouaid, C.
Pichon, E.
Siva, S.
Steinbusch, L.
Peretz, I.
Solomon, B.
Decoster, L.
Sawyer, W.
Allen, A.
Licour, M.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S738 - S739
[4] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Girard, N.
Mornex, F.
Christoph, D. C.
Fietkau, R.
Filippi, A. R.
Field, J.
Garrido Lopez, P.
McDonald, F.
Peters, S.
Klein, A. B.
Licour, M.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30
[5] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Christoph, D. C.
Behringer, D.
Emde, T. O.
Goekkurt, E.
Laack, E.
Mueller-Huesmann, H.
Schuett, P.
Schumann, C.
Seese, B.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
[6] Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Girard, Nicolas
Bar, Jair
Garrido, Pilar
Garassino, Marina C.
McDonald, Fiona
Mornex, Francoise
Filippi, Andrea R.
Smit, Hans J. M.
Peters, Solange
Field, John K.
Christoph, Daniel C.
Sibille, Anne
Fietkau, Rainer
Haakensen, Vilde D.
Chouaid, Christos
Markman, Ben
Hiltermann, T. Jeroen N.
Taus, Alvaro
Sawyer, William
Allen, Allison
Chander, Pratibha
Licour, Muriel
Solomon, Benjamin
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 181 - 193
[7] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
Filippi, A. R.
Bar, J.
Chouaid, C.
Christoph, D. C.
Field, J. K.
Fietkau, R.
Garassino, M. C.
Garrido, P.
Haakensen, V. D.
Kao, S.
Markman, B.
Mcdonald, F.
Mornex, F.
Moskovitz, M.
Peters, S.
Sibille, A.
Siva, S.
Heuvel, M. van den
Vercauter, P.
Anand, S.
Chander, P.
Licour, M.
Lima, A. R. de
Qiao, Y.
Girard, N.
ESMO OPEN, 2024, 9 (06)
[8] Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R)
Peters, S.
Christoph, D. C.
Field, J. K.
Fietkau, R.
Filippi, A. R.
Garassino, M.
Garrido, P.
McDonald, F.
Mornex, F.
Markman, B.
Solomon, B. J.
Anand, S.
Chander, P.
Qiao, Y.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S83 - S83
[9] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
Zhao, Binghao
Li, Huanzhang
Ma, Wenbin
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39
[10] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Park, Cheol-Kyu
Oh, Hyung-Joo
Kim, Young-Chul
Kim, Yong-Hyub
Ahn, Sung-Ja
Jeong, Won Gi
Lee, Jeong Yeop
Lee, Jae Cheol
Choi, Chang Min
Ji, Wonjun
Song, Si Yeol
Choi, Juwhan
Lee, Sung Yong
Kim, Hakyoung
Lee, Shin Yup
Park, Jongmoo
Yoon, Seong Hoon
Joo, Ji Hyeon
Oh, In-Jae
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054

← 1 2 3 4 5 →